Gocovri Reduces Transitions Between Dyskinesia and ‘Off’ Episodes, Trial Results Show

Gocovri Reduces Transitions Between Dyskinesia and ‘Off’ Episodes, Trial Results Show
Treatment with Gocovri (amantadine) reduced Parkinson’s dyskinesia — involuntary, jerky movements — and so-called “off” episodes, leading to longer periods of controlling motor symptoms, Phase 3 clinical trial results show. Parkinson’s motor fluctuations (off episodes) occur when the benefits of treatments such as levodopa wear off and symptoms re-emerge. About half of patients taking levodopa experience off periods, which become more frequent and severe ... read more
Source: Parkinson’s News TodayPublished on 2018-06-28By Jose Marques Lopes, PhD